staphylococcal infection cases
Conditions
Interventions
None listed
Sponsors
Nagasaki evaluation organization for clinical interventions
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (Infection control/infectious disease group) Among isolates from staphylococcal infection cases which occur during the observation period,those meeting (1) and (2),or (1) and (3) of the criteria (1) to (3) listed below will be collected. Two or more isolates from a single patient will be regarded as the same strain and should be counted as single isolate. 1) An isolate comfirmed to be MRSA. According to the standard methods of the National Committee for Crinical Laboratory Standards(NCCLS),incubate an isolate with 2% NaCl at 35 degrees centigrade for 24 hours;when the minimum inhibitory concentration of oxacillin against the isolate is 4ug/ml or more,the isolate will be regarded as MRSA. Alternatively,an isolate can be tested with the NCCLS disk diffusion method; even if the test shows oxacillin inhibition zone diameters of 10mm or less in the same incubation conditions as above,the isolated may be identified as MRSA. 2) An isolate from sterile sites,such as blood,ascites,pleural fluid,spinalfluid, and joint aspirates. 3) A case where MRSA is likely to be a causative organism and unlikely to be a colonizing organism. An isolate that can be identified as a causative organism if it is isolated from non-sterile sites(e.g.,sputum,pus,urine,stools). It is recommended to collect isolates from cases in which an ICD considered anti-MRSA chemotherapy is required. (Dermatology group) Staphylococcus aureus(including MRSA and methicillin-susceptible Staphylococcus aureus (MSSA)) will be included in the survey originated from specimens submitted to culture tests for potential skin infection from the out-patient dematology department or ward of each participating institution during the observation period.(This surveillance is mainly intended to collect MRSA isolates, but MSSA isolates will also be collected as control strains) (The dermatology group will use the same definition of MRSA as that for the infection control/infectious disease group)
Exclusion criteria
Exclusion criteria: none
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1) Infection control/infectious disease group The ratio of HA-MRSA to CA-MRSA in all MRSA isolates The proportion of CA-MRSA clones among strains that are not recognized as CA-MRSA (Involvement of CA-MRSA clones in hospital-acquired infection) 2)Dermatology group The proportion of MRSA isolates among all staphylococcal isolates from skin specimens Difference in the proportion of MRSA between in-patients and out-patients The proportion of CA-MRSA clones of all MRSA isolates 3)Both groups Ratio of HA-MRSA to CA-MRSA Isolation sites of HA-MRSA and CA-MRSA Drug susceptibility of HA-MRSA and CA-MRSA Genotyping of HA-MRSA and CA-MRSA Patient demographics of patients with HA-MRSA and those with CA-MRSA Clinical manifestations, treatment outlines, outcome, and clonarity of CA-MRSA infection | — |
Countries
Japan
Contacts
Public ContactKatsuniri Yanagihara
Nagasaki University Hospital Department of Laboratory Medicine
Outcome results
None listed